These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 15775358)
21. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500 [TBL] [Abstract][Full Text] [Related]
22. Calcitriol ointment: a review of a topical vitamin D analog for psoriasis. Sigmon JR; Yentzer BA; Feldman SR J Dermatolog Treat; 2009; 20(4):208-12. PubMed ID: 19444692 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Choi M; Makishima M Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936 [TBL] [Abstract][Full Text] [Related]
24. Immunomodulating effects of vitamin D analogs in hemodialysis patients. Seibert E; Levin NW; Kuhlmann MK Hemodial Int; 2005 Oct; 9 Suppl 1():S25-9. PubMed ID: 16223440 [TBL] [Abstract][Full Text] [Related]
25. Synthesis of all possible A-ring diastereomers at the 1- and 3-positions of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71) using C2-symmetrical epoxide as a common starting material. Kubodera N; Hatakeyama S Anticancer Res; 2009 Sep; 29(9):3571-8. PubMed ID: 19667150 [TBL] [Abstract][Full Text] [Related]
32. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Pramanik R; Asplin JR; Lindeman C; Favus MJ; Bai S; Coe FL Cell Immunol; 2004; 232(1-2):137-43. PubMed ID: 15876428 [TBL] [Abstract][Full Text] [Related]
33. The vitamin D3 pathway in human skin and its role for regulation of biological processes. Lehmann B Photochem Photobiol; 2005; 81(6):1246-51. PubMed ID: 16162035 [TBL] [Abstract][Full Text] [Related]
34. Vitamin D analogs and coactivators. Eelen G; Verlinden L; De Clercq P; Vandewalle M; Bouillon R; Verstuyf A Anticancer Res; 2006; 26(4A):2717-21. PubMed ID: 16886682 [TBL] [Abstract][Full Text] [Related]
35. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941 [TBL] [Abstract][Full Text] [Related]
36. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies. Hudson JQ Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241 [TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer: potential therapeutic benefits of Vitamin D. Jiménez-Lara AM Int J Biochem Cell Biol; 2007; 39(4):672-7. PubMed ID: 17157547 [TBL] [Abstract][Full Text] [Related]
38. [Recent medication to renal osteodystrophy]. Tabata T Clin Calcium; 2003 Mar; 13(3):333-9. PubMed ID: 15775100 [TBL] [Abstract][Full Text] [Related]
39. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Trémezaygues L; Reichrath J Dermatoendocrinol; 2011 Jul; 3(3):180-6. PubMed ID: 22110777 [TBL] [Abstract][Full Text] [Related]
40. The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in? Kim GK J Clin Aesthet Dermatol; 2010 Aug; 3(8):46-53. PubMed ID: 20877542 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]